LPL Financial
PGNX

LPL Financial’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

LPL Financial’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,124
Closed -$50K – 3546
2020
Q1 		$50K Buy
13,124
+2,953
+29% +$12.7K ﹤0.01% 3090
2019
Q4 		$52K Sell
10,171
-408
-4% -$2.16K ﹤0.01% 3273
2019
Q3 		$53K Sell
10,579
-1,048
-9% -$5.23K ﹤0.01% 3202
2019
Q2 		$72K Sell
11,627
-473
-4% -$2.28K ﹤0.01% 3183
2019
Q1 		$56K Buy
12,100
+1,228
+11% +$5.56K ﹤0.01% 3114
2018
Q4 		$46K Sell
10,872
-1,151
-10% -$5.86K ﹤0.01% 3009
2018
Q3 		$75K Sell
12,023
-1,322
-10% -$10.2K ﹤0.01% 3143
2018
Q2 		$107K Sell
13,345
-111
-0.8% -$847 ﹤0.01% 3099
2018
Q1 		$100K Buy
13,456
+2,415
+22% +$16.1K ﹤0.01% 3078
2017
Q4 		$66K Buy
11,041
+52
+0.5% +$316 ﹤0.01% 2964
2017
Q3 		$81K Buy
+10,989
New +$69.8K ﹤0.01% 2791
2017
Q2 		– Sell
-14,693
Closed -$133K – 3032
2017
Q1 		$133K Sell
14,693
-358
-2% -$3.57K ﹤0.01% 2576
2016
Q4 		$130K Buy
+15,051
New +$111K ﹤0.01% 2555

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

LPL Financial's PGNX Position: Q2 2020 in Review

LPL Financial sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 13,124 shares — an estimated $50K sold.

LPL Financial first reported a position in PGNX in Q4 2016 and held it in 13 quarters. The position peaked at $133K in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • LPL Financial reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • LPL Financial sold 13,124 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $50K.
  • LPL Financial first reported a position in Progenics Pharmaceuticals Inc in Q4 2016 and held it in 13 quarters.
  • LPL Financial's Progenics Pharmaceuticals Inc position peaked at $133K in Q1 2017.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on LPL Financial's 13F filing for Q2 2020, filed 13 Aug 2020.